For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Cost of revenue | - | 7,099 | ||
| Total operating expenses | - | 50,398 | ||
| Revenue | 4,706 | 4,346 | ||
| Cost of revenue | 6,670 | - | ||
| Sales and marketing | 17,710 | 16,463 | ||
| General and administrative | 23,867 | 20,156 | ||
| Amortization of acquired intangible assets | 421 | 688 | ||
| Research and development | 5,678 | 5,992 | ||
| Total operating expenses | 54,346 | - | ||
| Operating loss | -49,640 | -46,052 | ||
| Interest income | 386 | 322 | ||
| Interest expense | 22 | 26 | ||
| Change in fair value - senior secured convertible note | -7,656 | - | ||
| Debt extinguishments loss - senior secured convertible note | 0 | -5,167 | ||
| Change in fair value - senior secured convertible note | - | -5,394 | ||
| Equity issuance cost extinguishment | -1,078 | - | ||
| Other income (expense), net | -8,370 | 523 | ||
| Loss before provision for income tax | -58,010 | -45,529 | ||
| Provision for income taxes | 0 | 0 | ||
| Net loss attributable to lucid diagnostics inc | -58,010 | -45,529 | ||
| Dividends-Series AAnd A1Preferred Stock | 0 | - | ||
| Less deemed dividend on series a and series a-1 convertible preferred stock | - | 7,496 | ||
| Dividends-Series BAnd B1Preferred Stock | 12,559 | - | ||
| Net loss attributable to lucid diagnostics inc. common stockholders | -70,569 | -53,025 | ||
| Basic EPS | -0.69 | -1.05 | ||
| Diluted EPS | - | -1.05 | ||
| Basic Average Shares | 101,946,871 | 50,515,773 | ||
| Diluted Average Shares | - | 50,515,773 | ||
Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. (LUCD)